Skip to main content
. 2018 Jan 15;48(1):26–39.

Table 1. Characteristics of Specific Groups in The Ten Publications That Have Been Included in This Study.

COUNTRY MASKING PATIENT SETTING DOSAGE DURATION ACTIVE COMPARATOR #PATINETS FINISHED THE STUDY SCALE P-VALUE AUTHORS
14 countries1 Double Blind N/A Placebo 8 weeks N/A 127 HAM N/A Henigsberd, 2012
14 countries1 Double Blind N/A 1 mg 8 weeks N/A 127 HAM <0.001 Henigsberd, 2012
14 countries1 Double Blind N/A 5 mg 8 weeks N/A 129 HAM <0.001 Henigsberd, 2012
14 countries1 Double Blind N/A 10 mg 8 weeks N/A 122 HAM <0.001 Henigsberd, 2012
USA Double Blind N/A Placebo 8 weeks N/A 157 MADRS N/A Jacobsen, 2015
USA Double Blind N/A 10 mg 8 weeks N/A 155 MADRS 0.058 Jacobsen, 2015
USA Double Blind N/A 20 mg 8 weeks N/A 150 MADRS 0.002 Jacobsen, 2015
USA Double Blind N/A Placebo 9 weeks Duloxetine 60 mg 161 MADRS N/A Mahableshwarkar January 2015
USA Double Blind N/A 15 mg 9 weeks Duloxetine 60 mg 147 MADRS 0.224 Mahableshwarkar January 2015
USA Double Blind N/A 20 mg 9 weeks Duloxetine 60 mg 154 MADRS 0.023 Mahableshwarkar January 2015
USA Double Blind N/A Duloxetine 60 mg 9 weeks Duloxetine 60 mg 152 MADRS <0.001 Mahableshwarkar January 2015
11 countries + USA2 Double Blind Inpatient and outpatient Placebo 8 weeks N/A 196 MADRS N/A Mclntyre, 2014
11 countries + USA2 Double Blind Inpatient and outpatient 10 mg 8 weeks N/A 195 MADRS <0.0001 Mclntyre, 2014
11 countries + USA2 Double Blind Inpatient and outpatient 20 mg 8 weeks N/A 207 MADRS <0.0001 Mclntyre, 2014
13 countries3 Double Blind Inpatient and outpatient Placebo 8 weeks Duloxetine 60 mg 158 MADRS Boulenger, 2014
13 countries3 Double Blind Inpatient and outpatient 15 mg 8 weeks Duloxetine 60 mg 151 MADRS <0.0001 Boulenger, 2014
13 countries3 Double Blind Inpatient and outpatient 20 mg 8 weeks Duloxetine 60 mg 151 MADRS <0.0001 Boulenger, 2014
13 countries3 Double Blind Inpatient and outpatient Duloxetine 60 mg 8 weeks Duloxetine 60 mg 147 MADRS <0.0001 Boulenger, 2014
17 countries4 Open Labelled + double Blind Inpatient and outpatient 5-10 mg 24 weeks N/A 492 MADRS 0.0035 Boulenger, 2012
14 countries5 Double Blind Inpatient and outpatient Vortioxetine 15/20 mg 12 weeks Agomelatine 25/50 mg 253 MADRS 0.0054 Montgomery, 2014
14 countries5 Double Blind Inpatient and outpatient Agomelatine 25/50 mg 12 weeks Agomelatine 25/50 mg 242 MADRS 0.0054 Montgomery, 2014
USA + 6 countries6 Double Blind N/A placebo 8 weeks Duloxetine 60 mg 128 HAM N/A Katona, 2012
USA + 6 countries6 Double Blind N/A Vortioxetine 5 mg 8 weeks Duloxetine 60 mg 136 HAM P = 0.0011 Katona, 2012
USA + 6 countries6 Double Blind N/A Duloxetine 60 mg 8 weeks Duloxetine 60 mg 128 HAM <0.0001 Katona, 2012
USA Double Blind N/A Placebo 8 weeks Duloxetine 60 mg N/A MADRS N/A Mahableshwarkar, 2014
USA Double Blind N/A Duloxetine 60 mg 8 weeks Duloxetine 60 mg N/A MADRS <0.001 Mahableshwarkar, 2014
USA Double Blind N/A Vortioxetine 15 mg 8 weeks Duloxetine 60 mg N/A MADRS 0.224 Mahableshwarkar, 2014
USA Double Blind N/A Vortioxetine 20 mg 8 weeks Duloxetine 60 mg N/A MADRS 0.023 Mahableshwarkar, 2014
11 Countries7 Double Blind Outpatient Placebo 6 weeks Venlafaxine 225 mg 105 MADRS N/A Alvarez, 2012
11 Countries7 Double Blind Outpatient 5 mg 6 weeks Venlafaxine 225 mg 108 MADRS <0.0001 Alvarez, 2012
11 Countries7 Double Blind Outpatient 10 mg 6 weeks Venlafaxine 225 mg 100 MADRS <0.0001 Alvarez, 2012
11 Countries7 Double Blind Outpatient Venlafaxine 225 mg 6 weeks Venlafaxine 225 mg 113 MADRS <0.0001 Alvarez, 2012

Notes: 1Croatia, Germany, Finlandia, India, Japan, Latvia, Malaysia, Philippines, Poland, Romania, Rusia, Serbia, South Korea, Ukraine.

2Australia, Canada, Finland, France, Germany, Latvia, Mexico, Serbia, Slovakia, South Africa, Ukraine, and the US.

3Belgium, Estonia, Finland, France, Germany, Latvia, Lithuania, Norway, Russia, Slovakia, South Africa, Sweden and the Ukraine.

4Australia, Austria, Belgium, Canada, Finland, France, Germany, India, the Republic of Korea, Norway, Poland, South Africa, Sweden, Taiwan, Thailand, Turkey, the United Kingdom.

5Austria, Belgium, Bulgaria, Czech Republic, Estonia, Germany, Italy, Lithuania, Poland, Romania, Russia, Spain, Sweden and the UK.

6Canada, Finland, France, Germany, Sweden, Ukraine and the USA.

7Australia, Austria, Canada, Czech Republic, Finland, France, Italy, Malaysia, Slovakia, Spain, Sweden.